Direct Oral Anticoagulants (DOACs) have significantly improved anticoagulation therapy – due to their ease of use, ...

ROCKVILLE, Md. & EDMONTON, Alberta-- ( BUSINESS WIRE )--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Japanese Ministry of Health, Labour, and Welfare ...

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the ...

FDA drug alerts in pulmonology, including drug approvals/warnings, vaccine approvals, medical device recalls/updates, and ...

Exelixis, Inc. (Nasdaq: EXEL) today announced updated and final data from CABINET, a phase 3 pivotal trial evaluating ...

One contributing factor to the inconsistent pharmacokinetics of calcineurin inhibitors may be variable expression of functional CYP3A4 enzymes, CYP3A5 enzymes, and PGP efflux pumps. The ...

VRAYLAR is also contraindicated with concomitant use with strong and moderate CYP3A4 inhibitors / inducers. Due to the slow elimination of cariprazine and its metabolites, treatment with strong ...

VRAYLAR is also contraindicated with concomitant use with strong and moderate CYP3A4 inhibitors / inducers. Due to the slow elimination of cariprazine and its metabolites, treatment with strong and ...

The data also indicated that INF904 is a much weaker inhibitor of CYP3A4/5, with an IC50 value of 62 µM, compared to 1.7 µM for avacopan. CYP3A4/5 enzymes play an important role in the ...